FucoID Technology Platform for Identifying Tumor Antigen-Specific T Cells

The reactivation and clonal expansion of tumor-specific antigen (TSA)-reactive T cells are critical to the success of tumor-infiltrating lymphocyte (TIL)-based therapies. In many emerging personalized cancer therapies, the key to success is to find the sometimes elusive TSA-reactive T cells, then create more of these cells outside the patient's body, and then reintroduce them for tumor treatment. However, an unmet need in this field is the ability to identify useful tumor-infiltrating immune cells more quickly and accurately. Due to its heterogeneous composition, there is no reliable marker that can specifically identify the composition of TSA-responsive T cells.

At Creative Biolabs, we have developed a new technology, FucoID, named after the enzyme fucosyltransferase, which plays a key role in "labeling" the surface of the desired immune cells so that they can be seen and captured. Through this interaction-dependent labeling method, the universal FucoID platform can detect endogenous antigen-specific T cells to study their biological characteristics. Featuring genetic manipulation-free and fast turnover cycle characteristics, FucoID should have the potential to accelerate the pace of personalized cancer treatment.

FucoID Platform: A Fast, Precise Tool Identifies Tumor-Targeting T Cells

FucoID, tumor-lysate primed DCs presenting TSAs, acts as a "living" tetramer, equipped with an enzyme that induces proximity-based transfer of fucosylated biotin (Fuc-Bio) tags to the surface of T cells that interact with the DCs. Specifically, the enzyme is loaded on dendritic cells, which are immune cells that can present tumor-specific substances to the required T cells. When cells interact, enzymes transfer tags to anti-tumor cells, so scientists can detect them with fluorescent probes and extract them from samples.

Fig.1 Schematic representation of FucoID for the labeling of cell-cell interactions. (Liu, 2020)

Features of Our FucoID Platform

• Fucosyl-biotinylation enables detect endogenous tumor antigen-specific T cells.
• FucoID possesses genetic manipulation-free procedures and has the potential to accelerate the pace of personalized cancer treatment.
• FucoID can quickly take stock of tumor-specific T cells in patients.
• FucoID relies on bioinformatics or genetic manipulation, which is faster than today's methods and has a quick turnover cycle.

FucoID technology eliminates important obstacles to the study of tumor-specific T cells and will be very useful to both basic scientists and clinicians. If you are interested in our services, please send an email to contact us, and our team will get back to you as soon as possible.

Reference

1. Liu, Z., et al. (2020). Detecting Tumor Antigen-Specific T Cells via Interaction-Dependent Fucosyl-Biotinylation. Cell, 183(4), 1117-1133.

For Research Use Only | Not For Clinical Use